Most tools that estimate biological age need two blood draws months apart, tracking how markers move over time. A team reviewing evidence across diet, medication, and genetic studies (reported September 2026 in a Nature Aging-family analysis, per Technology Networks) instead went hunting for signals that shift with pace of aging even in a single snapshot: things like DNA methylation patterns, inflammatory proteins, and metabolic markers that move faster in people aging quickly than in people the same chronological age aging slowly. They narrowed a long list of candidates down to 12 that showed consistent movement across the studies they reviewed. None of the 12 has been validated in a prospective trial that follows people forward and checks whether the snapshot actually predicted who got sick first.

The distinction that matters here is between a marker that correlates with aging and one that predicts it. Pace-of-aging science already has one validated example, DunedinPACE, built from the Dunedin cohort that followed the same New Zealanders for four decades. That is what buys credibility: decades of prospective data showing the pace measure actually tracked who developed disease. A 12-marker panel identified by reviewing existing literature has not run that gauntlet, and a marker that looks promising in a review of past studies is a hypothesis, not a clock. Longevity clinics will likely market single-draw pace tests before that validation exists. The panel is worth watching for what a five-year follow-up study shows, not for what a blood test sold this year claims it can tell you.